ADARB1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the ADARB1 gene in a human colorectal adenocarcinoma background. This heterogeneous cell pool contains diverse ADARB1 disruptions, providing a robust and representative model that minimizes clonal artifacts while preserving the functional diversity inherent in polyclonal editing outcomes.
The HT29 host cell line is an epithelial colorectal adenocarcinoma model isolated from a primary tumor. It carries an inactivating APC mutation leading to constitutive Wnt/??-catenin signaling, a hallmark of colorectal tumorigenesis. HT29 is extensively used to investigate cancer cell proliferation, differentiation, and drug responses, making it a relevant platform to study the role of RNA editing in colorectal cancer.
ADARB1 encodes an adenosine deaminase that catalyzes site-selective A-to-I editing in dsRNA, which can result in amino acid recoding. The best-characterized target is GRIA2 (GluA2), where editing at the Q/R site changes a glutamine codon to arginine, altering calcium permeability of AMPA receptors. ADARB1 also edits HTR2C, FLNA, and COPA, thereby modulating neurotransmitter signaling and cytoskeletal organization. The enzyme is induced by type I interferons (IFN-??/??) through STAT factors and interacts with ADAR1, PKR (EIF2AK2), and PACT. Functionally, ADARB1 intersects with innate immune signaling via MDA5/MAVS/NF-??B, suggesting a role in buffering dsRNA-driven inflammatory responses.
In the HT29 colorectal cancer context, ADARB1 knockout may uncover editing-dependent regulatory mechanisms that influence tumor behavior. Loss of A-to-I editing could perturb cell adhesion, alter responses to interferon, or modify the activity of key oncogenic pathways. This model is particularly useful for dissecting how RNA editing shapes the interplay between cancer cells and the innate immune system, potentially revealing vulnerabilities that can be therapeutically exploited.
Researchers can employ this polyclonal knockout pool in a wide array of assays, including RNA-seq and Sanger sequencing to profile editing changes, RT-qPCR to measure transcript levels, and Western blotting or immunofluorescence for protein detection. Functional investigations may utilize MTT proliferation assays, colony formation assays, migration and invasion assays, and apoptosis assays to assess impacts on growth and metastasis. The model is also well-suited for screening drug responses tied to editing status and for analyzing the crosstalk between interferon signaling and RNA editing. For additional information or custom project inquiries, please contact Ascent Research.
